Neuromuscular Disease News

The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.

A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.

The FDA has granted rare pediatric disease designation to an investigational oligonucleotide for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping, according to the manufacturer.

The FDA has granted Regenerative Medicine Advanced Therapy designation to an autologous, fully human CD19 chimeric antigen receptor T-cell therapy candidate, to treat those with progressive myasthenia gravis.

An investigational, fully human monoclonal antibody developed as a muscle-targeted therapy for spinal muscular atrophy showed sustained motor function improvements at 48 months, according to the manufacturer.

The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

Prenatal exposure to ambient air pollution was associated with increased risk for children developing cerebral palsy, according to cohort study results published in JAMA Network Open.

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.